News headlines about Momenta Pharmaceuticals (NASDAQ:MNTA) have trended positive recently, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Momenta Pharmaceuticals earned a daily sentiment score of 0.28 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 44.5704719193529 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
A number of equities research analysts recently commented on the stock. Stifel Nicolaus raised shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price target for the stock from $18.00 to $21.00 in a report on Thursday, February 22nd. BidaskClub upgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, February 13th. Zacks Investment Research lowered shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, December 4th. Finally, ValuEngine upgraded shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 23rd. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $15.33.
Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) traded down $0.08 during trading hours on Wednesday, hitting $18.32. 746,645 shares of the stock traded hands, compared to its average volume of 925,392. The company has a market capitalization of $1,437.25, a P/E ratio of -15.08 and a beta of 1.72. Momenta Pharmaceuticals has a 52-week low of $11.85 and a 52-week high of $19.25.
In related news, SVP Bruce Leicher sold 4,948 shares of the stock in a transaction that occurred on Wednesday, February 14th. The shares were sold at an average price of $15.22, for a total transaction of $75,308.56. Following the transaction, the senior vice president now owns 176,210 shares in the company, valued at $2,681,916.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Craig A. Wheeler sold 3,938 shares of the stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $16.46, for a total transaction of $64,819.48. Following the transaction, the chief executive officer now owns 239,869 shares in the company, valued at approximately $3,948,243.74. The disclosure for this sale can be found here. Over the last three months, insiders sold 106,502 shares of company stock valued at $1,661,696. 4.40% of the stock is owned by insiders.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.